Tactile Systems Technology IPO

7/28/2016

IPO

$40,000,000

We intend to use the net proceeds from this offering primarily as follows: approximately $5.0 million to expand our sales and marketing activities; approximately $5.0 million to expand our product development activities; approximately $3.0 million to expand our reimbursement and clinical activities; approximately $8.2 million to pay the cumulative accrued dividends to our Series A preferred stockholders (assuming a closing date of August 1, 2016 and an initial public offering price of $10.00 per share) as described in "Dividend Policy"; and the remainder for working capital, general and administrative expenses and other general corporate purposes.

Publicly-held

Medical Devices & Instruments

1331 Tyler St. NE 200
Minneapolis, MN 55413
USA

Tactile Systems Technology, Inc. (NASDAQ: TCMD) was founded in 1995 to develop and market a medical device for the effective treatment of lymphedema and venous insufficiencies. The Flexitouch Lymphedema System, Tactile System's patented 2-Phase Lymph Preparation & Drainage therapy system, is the result of over six years of research and development.